The epidemiology of dystonia: the Hannover epidemiology study
- PMID: 35948800
- PMCID: PMC9618521
- DOI: 10.1007/s00415-022-11310-9
The epidemiology of dystonia: the Hannover epidemiology study
Abstract
The prevalence of dystonia has been studied since the 1980s. Due to different methodologies and due to varying degrees of awareness, resulting figures have been extremely different. We wanted to determine the prevalence of dystonia according to its current definition, using quality-approved registries and based on its relevance for patients, their therapy and the health care system. We applied a service-based chart review design with the City of Hannover as reference area and a population of 525,731. Barrier-free comprehensive dystonia treatment in few highly specialised centres for the last 30 years should have generated maximal dystonia awareness, a minimum of unreported cases and a high degree of data homogeneity. Prevalence [n/1mio] and relative frequency is 601.1 (100%) for all forms of dystonia, 251.1 (42%) for cervical dystonia, 87.5 (15%) for blepharospasm, 55.2 (9%) for writer's cramp, 38.0 (6%) for tardive dystonia, 32.3 (5%) for musician's dystonia, 28.5 (5%) for psychogenic dystonia, 26.6 (4%) for generalised dystonia, 24.7 (4%) for spasmodic dysphonia, 20.9 (3%) for segmental dystonia, 15.2 (3%) for arm dystonia and 13.3 (2%) for oromandibular dystonia. Leg dystonia, hemidystonia and complex regional pain syndrome-associated dystonia are very rare. Compared to previous meta-analytical data, primary or isolated dystonia is 3.3 times more frequent in our study. When all forms of dystonia including psychogenic, generalised, tardive and other symptomatic dystonias are considered, our dystonia prevalence is 3.7 times higher than believed before. The real prevalence is likely to be even higher. Having based our study on treatment necessity, our data will allow better allocation of resources for comprehensive dystonia treatment.
Keywords: Arm dystonia; Blepharospasm; Botulinum toxin therapy; Cervical dystonia; Dystonia; Epidemiology; Functional dystonia; Generalised dystonia; Musician’s dystonia; Oromandibular dystonia; Prevalence; Psychogenic dystonia; Segmental dystonia; Spasmodic dysphonia; Tardive dystonia; Writer’s cramp.
© 2022. The Author(s).
Conflict of interest statement
DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, AbbVie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB—Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. FAS is founder and owner of IAB—Interdisciplinary Working Group for Movement Disorders. She received reimbursement from Abbot, AbbVie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB. RG has nothing to disclose. EA has nothing to disclose. JKK is a consultant to Medtronic and to Boston Scientific. His research is supported by Deutsche Forschungsgemeinschaft (Project #201925000).
Similar articles
-
Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?J Neural Transm (Vienna). 2024 Dec 24. doi: 10.1007/s00702-024-02845-4. Online ahead of print. J Neural Transm (Vienna). 2024. PMID: 39718623
-
[Treatment of focal dystonia with botulinum toxin A].Wien Klin Wochenschr. 2001;113 Suppl 4:6-10. Wien Klin Wochenschr. 2001. PMID: 15506045 Review. German.
-
Epidemiology of primary focal dystonias in the western area of Tottori prefecture in Japan: Comparison with prevalence evaluated in 1993.Mov Disord. 2006 Sep;21(9):1503-6. doi: 10.1002/mds.20986. Mov Disord. 2006. PMID: 16755586
-
High prevalence of primary focal dystonia in the Faroe Islands.Acta Neurol Scand. 2016 Jan;133(1):55-60. doi: 10.1111/ane.12438. Epub 2015 Jun 4. Acta Neurol Scand. 2016. PMID: 26041438
-
Botulinum Toxin Therapy in Writer's Cramp and Musician's Dystonia.Toxins (Basel). 2021 Dec 14;13(12):899. doi: 10.3390/toxins13120899. Toxins (Basel). 2021. PMID: 34941736 Free PMC article. Review.
Cited by
-
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study.J Neural Transm (Vienna). 2025 Feb;132(2):257-264. doi: 10.1007/s00702-024-02839-2. Epub 2024 Oct 7. J Neural Transm (Vienna). 2025. PMID: 39370479 Free PMC article.
-
Spasmodic dysphonia: the need for a combined neurological and phoniatric approach.J Neural Transm (Vienna). 2025 Apr;132(4):603-608. doi: 10.1007/s00702-024-02868-x. Epub 2024 Dec 24. J Neural Transm (Vienna). 2025. PMID: 39718622 Free PMC article.
-
Deep brain stimulation for dystonia treatment in cerebral palsy: efficacy exploration.Exp Biol Med (Maywood). 2025 Jun 9;250:10330. doi: 10.3389/ebm.2025.10330. eCollection 2025. Exp Biol Med (Maywood). 2025. PMID: 40552018 Free PMC article.
-
The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review.Eur Psychiatry. 2025 Feb 10;68(1):e36. doi: 10.1192/j.eurpsy.2025.18. Eur Psychiatry. 2025. PMID: 39925222 Free PMC article.
-
Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.J Neurol. 2023 Mar;270(3):1524-1530. doi: 10.1007/s00415-022-11424-0. Epub 2022 Nov 24. J Neurol. 2023. PMID: 36434127 Free PMC article.
References
-
- Dressler D, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, Chung TM, Frucht S, Garcia-Ruiz PJ, Kaelin A, Kaji R, Kanovsky P, Laskawi R, Micheli F, Orlova O, Relja M, Rosales R, Slawek J, Timerbaeva S, Warner TT, Adib Saberi F. Strategies for treatment of dystonia. J Neural Transm. 2016;123:251–258. doi: 10.1007/s00702-015-1453-x. - DOI - PubMed
-
- Dressler D, Bhidayasiri R, Boholega S, Chana P, Chien S, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Koçer S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F. Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. J Neurol. 2018;265:856–862. doi: 10.1007/s00415-018-8759-1. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources